ArticleJournal of the American Heart Association2022
Cardiovascular Risk and Treatment Outcomes in Severe Hypercholesterolemia: A Nationwide Cohort Study.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Protective effects of icariin in atherosclerotic cardiovascular disease: mechanistic basis, post-ischemic protection and translational limitations.Pharmaceutical biology · 2026Review
- Assessing the impact of aggressive versus intermediate LDL-C goal achievement in Asian adults: a retrospective cohort study using national health insurance service-senior cohort.Lipids in health and disease · 2025Article
- Prevalence of Severe Hypercholesterolemia and Familial Hypercholesterolemia Phenotype in Patients with Acute Coronary Syndrome.Medicina (Kaunas, Lithuania) · 2025Article
- Lipoprotein cholesterol ratios and cardiovascular disease risk in US adults: a cross-sectional study.Frontiers in nutrition · 2025Article
- 2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea.Journal of lipid and atherosclerosis · 2022Review
- 2022 Consensus statement on the management of familial hypercholesterolemia in Korea.The Korean journal of internal medicine · 2022Review
- Impact of Severe Hypercholesterolemia on Cardiovascular Risk in Individuals With or Without Diabetes Mellitus.Journal of lipid and atherosclerosis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This study aimed to evaluate the cardiovascular risk and outcomes after lipid reduction in patients with severe hypercholesterolemia using a nationwide cohort. Methods and Results This study used the database from the National Health Insurance Service of Korea. Among individuals who underwent regular health examination and follow-up, 2 377 918 were enrolled and categorized into 3 groups with severe hypercholesterolemia according to low-density lipoprotein cholesterol (LDL-C) levels, namely, ≥260, 225 to 259, and 190 to 224 mg/dL groups, and a control group (<160 mg/dL). Risks of composite cardiovascular events (myocardial infarction, coronary revascularization, and ischemic stroke) and total mortality were compared. In statin new users, the outcomes after statin use were further analyzed according to posttreatment LDL-C levels. The prevalence of individuals with LDL-C≥190 mg/dL was 1 of 106. Adjusted hazard ratios of composite events and total mortality (median follow-up, 6.1 years) in the groups ranged up to 2.4 (log-rank
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.